The SUMMIT study demonstrates that tirzepatide significantly improves symptoms and prognosis of heart failure in obese patients.
Heart failure with preserved ejection fraction (HFpEF) is one of the most frequent and challenging forms of heart failure to treat, particularly affecting obese patients. The SUMMIT study, published in the New England Journal of Medicine in 2024, provides major results on the efficacy of tirzepatide in this indication.
Heart failure with preserved ejection fraction: a therapeutic challenge
HFpEF accounts for approximately 50% of all heart failure cases. Unlike heart failure with reduced ejection fraction (HFrEF), where numerous treatments have proven effective, HFpEF had very few validated therapeutic options. Obesity is a major risk factor for HFpEF, with excess weight leading to volume overload and diastolic dysfunction.
Design of the SUMMIT study
SUMMIT is a randomized, double-blind, placebo-controlled trial that enrolled 731 patients with HFpEF (LVEF ≥ 50%) and obesity (BMI ≥ 30). Participants received tirzepatide (maximum tolerated dose up to 15 mg) or placebo for 52 weeks. The primary composite endpoint included cardiovascular death and events related to the worsening of heart failure.
Main results
Tirzepatide reduced the primary composite endpoint by 38% compared to placebo (HR 0.62; 95% CI 0.41-0.95; p=0.026). More specifically:
- Cardiovascular death or hospitalization for heart failure: 38% reduction
- Improvement in the Kansas City Cardiomyopathy Questionnaire (quality of life): +6.9 points vs +1.8 under placebo
- 6-minute walk distance: 18.2 meters improvement (vs -2.4 under placebo)
- NT-proBNP (heart failure marker): 30% reduction
- Body weight: 13.9% loss vs 2.2% under placebo
Explanatory mechanisms
The cardiovascular benefits of tirzepatide in HFpEF are explained by several complementary mechanisms:
- Weight loss: reduction of cardiac preload and afterload
- Reduction of epicardial fat: improvement of diastolic function
- Anti-inflammatory effects: reduction of CRP and pro-inflammatory cytokines
- Improvement of insulin sensitivity: reduction of myocardial metabolic stress
- Moderate diuretic effects: reduction of hydrosaline retention
Clinical implications
SUMMIT is a study that could transform the management of HFpEF. If confirmed by further studies, tirzepatide could become the first specific treatment for HFpEF in obese patients, filling a major therapeutic gap.
For obese heart failure patients, tirzepatide offers a double benefit: improvement in heart failure and significant weight loss. Monitoring weight, dyspnea, and exercise capacity is essential. The MounjaGO app allows you to document these parameters for your cardiology consultations. MounjaGO offers 5€ for life (one-time payment, zero subscription), is a Web app — no installation required, and uses 100% local storage (maximum privacy).
FAQ: Mounjaro and heart failure
Is Mounjaro indicated for heart failure?
Not yet officially. The SUMMIT study provides strong evidence, but formal indication for HFpEF has not yet been obtained. Cardiologists can, however, prescribe tirzepatide for obesity in heart failure patients.
Is tirzepatide dangerous for the heart?
No. On the contrary, SUMMIT demonstrates a significant cardiovascular benefit. Tirzepatide does not cause significant tachycardia and does not increase the risk of arrhythmia.
Can Mounjaro be taken with diuretics?
Yes. In SUMMIT, the majority of patients were taking diuretics. An adjustment of diuretic doses may be necessary during weight loss to avoid dehydration.